Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, and HIV-related health complications and treatments.
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
Viral and host mediators of non-suppressible HIV-1 viremia
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana
Recommendations for the Management of Drug–Drug Interactions Between the <scp>COVID</scp>‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV
SARS-CoV-2 viral load is associated with increased disease severity and mortality
Determination of RNA structural diversity and its role in HIV-1 RNA splicing
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
Author Correction: Determination of RNA structural diversity and its role in HIV-1 RNA splicing
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers
Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30
Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study
Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study
High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation
Metagenomic Sequencing of an Echovirus 30 Genome From Cerebrospinal Fluid of a Patient With Aseptic Meningitis and Orchitis
International AIDS Society global scientific strategy: towards an HIV cure 2016
Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption
Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257
Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV
Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
Viral Infection and Inflammation Workshop 2024
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
A Pilot Clinical Trial for HIV-1 Eradication
A Pilot Clinical Trial for HIV-1 Eradication
A Pilot Clinical Trial for HIV-1 Eradication